These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 24003687)
21. The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication. Gidman W; Meacock R; Symmons D Curr Rheumatol Rep; 2015 May; 17(5):31. PubMed ID: 25874347 [TBL] [Abstract][Full Text] [Related]
22. [Current therapy of polyarticular forms of juvenile idiopathic arthritis]. Hospach A; Rühlmann JM; Weller-Heinemann F Z Rheumatol; 2016 Apr; 75(3):284-91. PubMed ID: 27001055 [TBL] [Abstract][Full Text] [Related]
23. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis. Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822 [TBL] [Abstract][Full Text] [Related]
24. Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives. Wahezi DM; Ilowite NT Expert Opin Pharmacother; 2013 Jun; 14(8):975-89. PubMed ID: 23528005 [TBL] [Abstract][Full Text] [Related]
25. A retrospective study on 158 Thai patients with juvenile idiopathic arthritis followed in a single center over a 15-year period. Vilaiyuk S; Soponkanaporn S; Jaovisidha S; Benjaponpitak S; Manuyakorn W Int J Rheum Dis; 2016 Dec; 19(12):1342-1350. PubMed ID: 26176300 [TBL] [Abstract][Full Text] [Related]
27. Juvenile idiopathic arthritis--current and future therapies. Kahn P Bull NYU Hosp Jt Dis; 2009; 67(3):291-302. PubMed ID: 19852753 [TBL] [Abstract][Full Text] [Related]
28. Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment. Nalbanti P; Kanakoudi-Tsakalidou F; Trachana M; Pratsidou-Gertsi P; Farmaki E; Bamidis P; Papachristou F Rheumatol Int; 2018 Jul; 38(7):1241-1250. PubMed ID: 29845429 [TBL] [Abstract][Full Text] [Related]
29. Juvenile idiopathic arthritis in the new world of biologics. Ostring GT; Singh-Grewal D J Paediatr Child Health; 2013 Sep; 49(9):E405-12. PubMed ID: 23647810 [TBL] [Abstract][Full Text] [Related]
30. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort. Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065 [TBL] [Abstract][Full Text] [Related]
31. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Ungar WJ; Costa V; Burnett HF; Feldman BM; Laxer RM Semin Arthritis Rheum; 2013 Jun; 42(6):597-618. PubMed ID: 23337074 [TBL] [Abstract][Full Text] [Related]
32. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. Ong MS; Ringold S; Kimura Y; Schanberg LE; Tomlinson GA; Natter MD; Arthritis Rheumatol; 2021 Oct; 73(10):1910-1920. PubMed ID: 34105303 [TBL] [Abstract][Full Text] [Related]
33. Update on biologicals for treatment of juvenile idiopathic arthritis. Horneff G Expert Opin Biol Ther; 2013 Mar; 13(3):361-76. PubMed ID: 23289865 [TBL] [Abstract][Full Text] [Related]
34. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance. Horton DB; Onel KB; Beukelman T; Ringold S J Rheumatol; 2017 Mar; 44(3):352-360. PubMed ID: 28148696 [TBL] [Abstract][Full Text] [Related]
35. Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis. Buckley L; Ware E; Kreher G; Wiater L; Mehta J; Burnham JM J Rheumatol; 2020 Feb; 47(2):273-281. PubMed ID: 31308202 [TBL] [Abstract][Full Text] [Related]
36. The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study. Aygun D; Sahin S; Adrovic A; Barut K; Cokugras H; Camcıoglu Y; Kasapcopur O Clin Rheumatol; 2019 Apr; 38(4):1025-1030. PubMed ID: 30448935 [TBL] [Abstract][Full Text] [Related]
37. Growth and body mass index in a cohort of patients with juvenile idiopathic arthritis: effects of second line treatments. Marino A; Stagi S; Simonini G; Carli N; Caparello MC; Giani T; Pagnini I; De Masi S; Cimaz R Clin Exp Rheumatol; 2018; 36(5):929-933. PubMed ID: 30148444 [TBL] [Abstract][Full Text] [Related]
38. The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis. Hügle B; Horneff G Expert Opin Pharmacother; 2016; 17(5):703-14. PubMed ID: 26678914 [TBL] [Abstract][Full Text] [Related]
39. Considerations for the Primary Care Provider Caring for Patients with Juvenile Idiopathic Arthritis Receiving Biologic Therapy. Zic C Pediatr Ann; 2022 Feb; 51(2):e54-e56. PubMed ID: 35156891 [TBL] [Abstract][Full Text] [Related]
40. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Hayward K; Wallace CA Arthritis Res Ther; 2009; 11(1):216. PubMed ID: 19291269 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]